title: Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint.
abstract: OBJECTIVE
  To study the efficacy of hylan G-F 20 in the treatment of osteoarthritis (OA) of the hip joint.
  
  
  METHODS
  Prospective within-group study.
  
  
  METHODS
  Musculoskeletal rehabilitation clinic.
  
  
  METHODS
  Twenty-two patients (25 hips) with hip joint OA who had failed to find pain relief from conservative methods such as physical therapy, exercises, and steroid injections. Demographics included 14 men and 11 women (mean age, 56.4y), 21 of whom had mild to moderate OA and 4 of whom had severe OA of the hips.
  
  
  METHODS
  Each hip joint was injected with 2mL of hylan G-F 20 at 2, 3, and 4 weeks and fluoroscopic lavage with 100mL of normal saline at week 1. All patients had standard hip exercise regimen after the injection.
  
  
  METHODS
  American Academy of Orthopaedic Surgeons (AAOS) Lower Limb Core Scale score and visual numeric pain score.
  
  
  RESULTS
  At 1-year follow-up, the AAOS Lower Limb Core Scale score improved from a preinjection mean of 44.2 to a follow-up mean of 86.1 (P<.05). The mean visual numeric pain score improved from a preinjection mean of 8.7 (range, 6.4-10) to a follow-up mean of 2.3 (range, 0-7.2). The overall success rate was 84%. In patients with mild to moderate OA, the mean pain score decreased from a preinjection value of 7.8 to a follow-up value of 1.7. The success rate was 90.5% in that subgroup. In patients with severe OA, the mean pain score decreased from a preinjection value of 9.1 to a follow-up value of 3.8. The success rate was 50% in that subgroup. There were no complications related to the injection.
  
  
  CONCLUSIONS
  Use of hylan G-F 20 injection is a viable option for treatment of mild to moderate OA of the hip joint.
authors.affiliation: Department of Rehabilitation Medicine, Cornell University Medical Center, New York, NY, USA.
authors.forename: Vijay B
authors.initials: VB
authors.lastname: Vad
authors.forename: Durgadas
authors.initials: D
authors.lastname: Sakalkale
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Sculco
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Wickiewicz
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005471:Fluoroscopy; D006621:Hip Joint / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D006820:Hyaluronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation; D010147:Pain Measurement / Q000379:methods; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: C049816:hylan; D006820:Hyaluronic Acid